Document Detail

Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil.
MedLine Citation:
PMID:  19480735     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Propylthiouracil is one of the thionamides used in the treatment of Graves' disease. The drug has serious side effects and long-term treatment might be needed to achieve remission. We designed this study to evaluate the clinical and thyroid Doppler characteristics that might predict time to remission and treatment failure in propylthiouracil treated Graves' patients. METHODS: 26 patients, among 134 presenting to our university hospital outpatient clinic between Feb -July 2007 and with first time diagnosis of clinical thyroid dysfunction, were clinically and ultasonographically diagnosed with Graves' disease. Doppler parameters, serum thyrotropin, free thyroxine and free triiodothyronine were measured at the beginning of the study and thyroid studies were repeated every 4 weeks until remission. Propylthiouracil 300 mg/day was started for each patient at the time of diagnosis and doses were titrated according to repeat thyroid studies. Patients were treated and followed up for 18 months. RESULTS: Treatment failure was associated with smoking (P = 0.001) and male gender (P= 0.037). Stepwise multiple regression analysis revealed that age, free thyroxine and superior thyroid artery flow rate were predictors of time to remission (P= 0.001, 0.002 and 0.003, respectively). CONCLUSION: The time to remission in Graves patients treated with propylthiouracil can be predicted using age, serum free thyroxine and superior thyroid artery flow rate. This may help early consideration of alternative treatment for the patients requiring prolonged treatment for remission or for those who fail medical treatment. This would decrease unnecessary, long-term propylthiouracil exposure with its serious side effects.
Hakan Cinemre; Cemil Bilir; Feyzi Gokosmanoglu; Nermin Akdemir; Besir Erdogmus; Ramazan Buyukkaya
Related Documents :
18287455 - Percutaneous ethanol injection of hyperfunctioning thyroid nodules: long-term follow-up...
1900575 - Administration of thyroxine in treated graves' disease. effects on the level of antibod...
2724215 - Cervical thymectomy in the treatment of myasthenia gravis.
20641075 - Evaluation of intraoperative parathormone measurement for predicting successful surgery...
21643825 - Anterior single screw fixation of odontoid fracture with intraoperative iso-c 3-dimensi...
15808155 - Autologous cultivated conjunctival transplantation for pterygium surgery.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-01
Journal Detail:
Title:  Clinical and investigative medicine. Médecine clinique et experimentale     Volume:  32     ISSN:  1488-2353     ISO Abbreviation:  Clin Invest Med     Publication Date:  2009  
Date Detail:
Created Date:  2009-06-01     Completed Date:  2009-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804071     Medline TA:  Clin Invest Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  E199-205     Citation Subset:  IM    
Duzce University School of Medicine, Department of Internal Medicine, Konuralp, Duzce 81620,Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithyroid Agents / adverse effects,  therapeutic use*
Graves Disease / drug therapy*,  metabolism,  pathology*
Propylthiouracil / adverse effects,  therapeutic use*
Sex Factors
Thyroxine / metabolism
Treatment Failure
Reg. No./Substance:
0/Antithyroid Agents; 51-52-5/Propylthiouracil; 7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial baroreflex function in older adults with neurocardiogenic syncope.
Next Document:  Peptidic sequence "HSEAETGPP" is recognized by the sera of pars planitis patients.